Leptin was supposed to be the obesity drug. The hormone fat cells release to tell the brain the body has eaten enough works beautifully in the rare people born without it, and does almost nothing for common obesity, where the brain stops listening to a signal that is already running high. That failure, called leptin resistance, has been the field's central puzzle for three decades: if the body makes plenty of leptin, why does the brain act starved?
A mouse study published October 2 in the EMBO Journal ↗ narrows the puzzle to a single kind of cell. Working in mice made obese on a high-fat diet, the authors combined spatial transcriptomics (reading which genes are switched on, and where, across intact brain tissue) with single-nucleus RNA sequencing (the same read taken one cell nucleus at a time). Most leptin-receptor neurons in the hypothalamus, the brain's appetite hub, had gone quiet: raise leptin and they barely respond. One subgroup did not. The neurons that kept their full leptin sensitivity were the ones that also carry the receptor for GLP-1, the gut hormone behind semaglutide ↗ and liraglutide ↗.
That overlap is the story. GLP-1R ↗ is the most valuable target in metabolic medicine right now, the receptor the entire weight-loss drug class was built to hit. The new work says the cells defined by that receptor are also the brain's last leptin-sensitive holdouts once obesity sets in. Two appetite systems the field has largely studied apart turn out to converge on the same neurons.
The paper traces what those neurons do. The Lepr-plus, Glp1r-plus cells project onto and inhibit AgRP neurons, the hunger-driving cells that push an animal to eat more. Delete the leptin receptor from just this subgroup and the consequences stack up: leptin loses its appetite-suppressing effect, the overeating that a high-fat diet normally keeps in check comes back, and the animals gain more weight when offered palatable food. One finding the authors flag as unexpected. Cutting leptin signaling in these neurons quieted the microglial activation (the brain's resident immune cells switching into an inflammatory state) that usually tracks diet-induced obesity. That inflammation had been pinned on the diet itself. Here it follows leptin signaling instead.
This is not the first time the two receptors have been found in the same cell. A 2023 paper in the Journal of Clinical Investigation ↗ from Martin Myers' lab mapped a group of inhibitory neurons in the dorsomedial hypothalamus that co-express both receptors, showed that deleting leptin sensing from them produced obese, overeating mice, and found that liraglutide suppressed feeding through the GLP-1 receptor on leptin-receptor cells. That census counted eighteen distinct leptin-receptor populations in the region. What the new work adds is the obesity context: this is the one population that stays awake when the rest go deaf.
The honest caveat is that this is mouse anatomy, not a human drug result, and the paper tests the body's own leptin rather than any GLP-1 medicine. It does not show that semaglutide works by rescuing leptin signaling, and no one should read it that way. What it offers is a mechanistic reason the two drug stories diverged. Leptin flooded a brain that had stopped listening nearly everywhere. GLP-1 drugs land on the receptor that marks the one place still tuned in, the neurons wired to brake the hunger circuit.
For a field spending billions to engineer the next incretin, the map matters. If the GLP-1 receptor's weight-loss power runs partly through neurons that are also the brain's leptin gatekeepers, then the long-running idea of combining the two signals, which amylin and long-acting leptin analogs are already circling, has an address rather than a hope. The target was never just a receptor. It was a specific set of cells that kept listening after the rest of the brain tuned out.